Treatment of symptomatic coronary artery disease in patients with end-stage renal disease on hemodialysis with paclitaxel-eluting TAXUS stent
| Autor: | Jack L. Martin, Szymon Wiernek, Adam Janas, Robert G. Szewc, Blazej Trela, Barbara Wiernek, Paweł Buszman, R. Stefan Kiesz, Piotr P. Buszman |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Percutaneous coronary intervention Hematology medicine.disease End stage renal disease Coronary artery disease Nephrology Internal medicine Conventional PCI medicine Cardiology cardiovascular diseases Myocardial infarction Hemodialysis business Mace Dialysis |
| Zdroj: | Hemodialysis International. 19:402-411 |
| ISSN: | 1492-7535 |
| DOI: | 10.1111/hdi.12259 |
| Popis: | Percutaneous coronary intervention (PCI) utilizing drug-eluting stents is becoming a very common revascularization technique in the dialysis cohort; therefore, we sought to identify the impact of dialysis on outcomes in this group of patients. This is a multicenter registry comparing results of 290 patients (186 with normal kidney function, 104 on dialysis) who underwent PCI with exclusive use of paclitaxel-eluting TAXUS stent. The primary endpoint was an assessment of major adverse cardiac events (MACE) at 1- and 2-year observation. Mean follow-up was 23.3 ± 6.1 months. Results at 12 months showed: MACE 11.8% vs. 7.7% (P = not significant [ns]), composite major adverse cardiac and cerebrovascular events (MACCE) 12.4% vs. 11.5% (P = ns), all-cause death 2.7% vs. 8.6% (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text